Recent advances in understanding Spinal Muscular Atrophy (SMA) etiopathogenesis prompted development of potent intervention strategies and raised need for sensitive outcome measures capable of assessing disease progression and response to treatment. Several biomarkers have been proposed; nevertheless, no general consensus has been reached on the most feasible ones. We observed a wide range of measures over 1 year to assess their ability to monitor the disease status and progression
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle weaknes...
Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mu...
OBJECTIVE: To characterize the natural history of spinal muscular atrophy (SMA) over 24 months using...
Objective Recent advances in understanding Spinal Muscular Atrophy (SMA) etiopathogenesis prompted d...
Spinal muscular atrophy (SMA) is a lower motor neuron disease due to biallelic mutations in the SMN1...
Introduction: Nusinersen is a recent promising therapy approved for the treatment of spinal muscular...
<label>OBJECTIVES</label>Spinal Muscular Atrophy (SMA) presents challenges in (i) monitoring disease...
<div><p>Objectives</p><p>Spinal Muscular Atrophy (SMA) presents challenges in (i) monitoring disease...
Background: There is an unmet need for reliable biomarkers to predict disease severity, prognosis, a...
Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, is a rare, X-linked, lat...
The availability of disease modifying therapies for spinal muscular atrophy (SMA) has created an urg...
Objectives: Spinal Muscular Atrophy (SMA) presents challenges in (i) monitoring disease activity and...
In this thesis, I describe the natural history and clinical variability of spinal muscular atrophy (...
Recent unprecedented advances in treatment for spinal muscular atrophy (SMA) enabled patients to acc...
<div><p>Spinal muscular atrophy (SMA) is a monogenic disorder caused by loss of function mutations i...
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle weaknes...
Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mu...
OBJECTIVE: To characterize the natural history of spinal muscular atrophy (SMA) over 24 months using...
Objective Recent advances in understanding Spinal Muscular Atrophy (SMA) etiopathogenesis prompted d...
Spinal muscular atrophy (SMA) is a lower motor neuron disease due to biallelic mutations in the SMN1...
Introduction: Nusinersen is a recent promising therapy approved for the treatment of spinal muscular...
<label>OBJECTIVES</label>Spinal Muscular Atrophy (SMA) presents challenges in (i) monitoring disease...
<div><p>Objectives</p><p>Spinal Muscular Atrophy (SMA) presents challenges in (i) monitoring disease...
Background: There is an unmet need for reliable biomarkers to predict disease severity, prognosis, a...
Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, is a rare, X-linked, lat...
The availability of disease modifying therapies for spinal muscular atrophy (SMA) has created an urg...
Objectives: Spinal Muscular Atrophy (SMA) presents challenges in (i) monitoring disease activity and...
In this thesis, I describe the natural history and clinical variability of spinal muscular atrophy (...
Recent unprecedented advances in treatment for spinal muscular atrophy (SMA) enabled patients to acc...
<div><p>Spinal muscular atrophy (SMA) is a monogenic disorder caused by loss of function mutations i...
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle weaknes...
Proximal spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by mu...
OBJECTIVE: To characterize the natural history of spinal muscular atrophy (SMA) over 24 months using...